Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020

SAN DIEGO, July 30, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. NBIX will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday, August 6, 2020. Kyle Gano, Chief Business Development and Strategy Officer, will participate in a panel session titled "New Therapies Impacting the Epilepsy Treatment Landscape" at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical development programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-the-william-blair-biotech-focus-conference-2020-301103412.html

SOURCE Neurocrine Biosciences, Inc.